‘We need to change the current clinical trial infrastructure’: Medable
The company’s new chief scientific officer, a 30-year industry veteran, shares her informed thoughts on the future direction of the research field.
The company’s new chief scientific officer, a 30-year industry veteran, shares her informed thoughts on the future direction of the research field.
The two companies plan to collaboratively explore ways to combine 3D printing and nanotechnology, in order to create nanoparticle-enabled dosage forms.